CTOs on the Move

Progenity

www.progenity.com

 
Progenity, Inc. is a biotechnology company innovating in the fields of women`s health, gastrointestinal health, and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity`s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.progenity.com
  • 4330 La Jolla Village Drive
    San Diego, CA USA 92122
  • Phone: 855.293.2639

Executives

Name Title Contact Details
Paul Shabram
 Senior Vice President of Technical Operations Profile
Launa Saunders
 Director of IT, Sales and Marketing Platforms Profile
Troy Seelye
 Senior Vice President and Chief Information Officer Profile

Funding

Progenity raised $125M on 11/07/2017
Progenity raised $40M on 06/10/2021

Similar Companies

Specialty Flooring Systems Inc

Specialty Flooring Systems Inc is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micell Technologies

Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioPharm Engineered Systems

BioPharm Engineered Systems is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chelsea Therapeutics

Chelsea Therapeutics is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body`s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno`s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world`s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children`s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children`s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children`s Research Hospital.